- Home
- ACGL vs ARGX Comparison
ACGL vs ARGX Comparison
Compare ACGL & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACGL
- ARGX
- Stock Information
- Founded
- ACGL 2001
- ARGX 2008
- Country
- ACGL Bermuda
- ARGX Netherlands
- Employees
- ACGL N/A
- ARGX N/A
- Industry
- ACGL Property-Casualty Insurers
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACGL Finance
- ARGX Health Care
- Exchange
- ACGL Nasdaq
- ARGX Nasdaq
- Market Cap
- ACGL 35.1B
- ARGX 37.3B
- IPO Year
- ACGL 1995
- ARGX 2017
- Fundamental
- Price
- ACGL $90.99
- ARGX $623.82
- Analyst Decision
- ACGL Buy
- ARGX Strong Buy
- Analyst Count
- ACGL 16
- ARGX 20
- Target Price
- ACGL $118.69
- ARGX $634.50
- AVG Volume (30 Days)
- ACGL 1.9M
- ARGX 290.3K
- Earning Date
- ACGL 02-12-2025
- ARGX 10-31-2024
- Dividend Yield
- ACGL 5.50%
- ARGX N/A
- EPS Growth
- ACGL 91.75
- ARGX N/A
- EPS
- ACGL 14.88
- ARGX N/A
- Revenue
- ACGL $16,867,000,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- ACGL N/A
- ARGX $61.99
- Revenue Next Year
- ACGL $12.18
- ARGX $42.48
- P/E Ratio
- ACGL $6.12
- ARGX N/A
- Revenue Growth
- ACGL 32.50
- ARGX 85.56
- 52 Week Low
- ACGL $73.04
- ARGX $349.86
- 52 Week High
- ACGL $116.47
- ARGX $644.97
- Technical
- Relative Strength Index (RSI)
- ACGL 34.14
- ARGX 58.04
- Support Level
- ACGL $88.67
- ARGX $613.95
- Resistance Level
- ACGL $90.98
- ARGX $644.97
- Average True Range (ATR)
- ACGL 1.84
- ARGX 14.33
- MACD
- ACGL -0.49
- ARGX -0.42
- Stochastic Oscillator
- ACGL 19.92
- ARGX 50.28
About ACGL Arch Capital Group Ltd.
Arch Capital Group Ltd is a Bermuda company which writes insurance and reinsurance with operations in Bermuda, the United States, Canada, Europe, Australia and United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage two operating segments: corporate and other. The insurance segment provides specialty risk solutions to client across a variety of industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.